These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 26237403)
1. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403 [TBL] [Abstract][Full Text] [Related]
2. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914 [TBL] [Abstract][Full Text] [Related]
3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
10. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. Watkins JD; Sholukh AM; Mukhtar MM; Siddappa NB; Lakhashe SK; Kim M; Reinherz EL; Gupta S; Forthal DN; Sattentau QJ; Villinger F; Corti D; Ruprecht RM; AIDS; 2013 Jun; 27(9):F13-20. PubMed ID: 23775002 [TBL] [Abstract][Full Text] [Related]
11. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162 [TBL] [Abstract][Full Text] [Related]
12. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422 [TBL] [Abstract][Full Text] [Related]
14. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110 [TBL] [Abstract][Full Text] [Related]
15. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419 [TBL] [Abstract][Full Text] [Related]
16. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233 [TBL] [Abstract][Full Text] [Related]
17. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge. Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339 [TBL] [Abstract][Full Text] [Related]
18. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
19. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049 [TBL] [Abstract][Full Text] [Related]
20. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]